CYP46A1

Across TCGA pan-cancer cohorts, CYP46A1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP46A1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CYP46A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP46A1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

GBM, HNSC, and LUSC are the cancer types where CYP46A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.005	0.416	<.001	12	view →
HNSC	OS	Median	IV	0.130	0.733	.001	12	view →
LUSC	OS	Median	All	0.205	0.660	.024	11	view →
UCEC	OS	Median	IV	0.277	0.605	.013	6	view →
SKCM	DFS	Median	II,III,IV	0.899	0.668	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP46A1–GBM (OS)

Open the GBM breakdown →